Zirconium panitumumab Zr-89

DB19228InvestigationalProtein Based Therapies

Zirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Also known as: 89zr-labeled panitumumab · 89Zr-panitumumab

Resolves to

Compound

UNII9S814K02BB

Targets

P00533EGFR

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zirconium panitumumab Zr-89, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account